| Dr David William Hansen, MD | |
|
3229 E. Genesee St, Suite 1, Syracuse, NY 13214 | |
| (315) 464-5726 | |
| (315) 464-2510 |
| Full Name | Dr David William Hansen |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Pediatric Endocrinology |
| Location | 3229 E. Genesee St, Syracuse, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003105768 | NPI | - | NPPES |
| 1003105768 | Medicaid | WI | |
| 05233927 | Medicaid | NY | |
| 1003105768 | Medicaid | IN |
| Entity Name | Pediatric Service Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770539066 PECOS PAC ID: 9931007200 Enrollment ID: O20031223000483 |
News Archive
The U.S. recently celebrated the Fourth of July with dazzling fireworks displays in many cities. After the "oohs" and "ahhs" faded, some people might have wondered how the lingering gunpowder-scented smoke affected air quality.
In this PLoS Medicine editorial, the editors review progress toward the journal's goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project - a "comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors," a PLoS press release writes.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston's safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.
A discovery in the field of biomaterials may open new frontiers in stem and cancer cell manipulation and associated advanced therapy development.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David William Hansen, MD 725 East Adams St, 5th Fl, Syracuse, NY 13210 Ph: (315) 464-5726 | Dr David William Hansen, MD 3229 E. Genesee St, Suite 1, Syracuse, NY 13214 Ph: (315) 464-5726 |
News Archive
The U.S. recently celebrated the Fourth of July with dazzling fireworks displays in many cities. After the "oohs" and "ahhs" faded, some people might have wondered how the lingering gunpowder-scented smoke affected air quality.
In this PLoS Medicine editorial, the editors review progress toward the journal's goal of reflecting and addressing inequity in the burden of ill-health around the world as part of the Global Burden of Disease project - a "comprehensive work studying the burden of ill-health and death resulting from specific conditions, injuries, and risk factors," a PLoS press release writes.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has received its fourth patent. The patent, entitled "Methods and systems for dynamic gene expression profiling", with inventor Vladimir Slepnev, Ph.D., describes a novel method of quantitative analysis of gene expression allowing simultaneous interrogation of multiple genes in a single tube reaction.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston's safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.
A discovery in the field of biomaterials may open new frontiers in stem and cancer cell manipulation and associated advanced therapy development.
› Verified 1 days ago
Ms. Bonnie Lee Marr I, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 736 Irving Ave Ste 9100, Syracuse, NY 13210 Phone: 315-470-7379 Fax: 315-470-2923 | |
Dr. Audrey Victoria Vandewall, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 750 E Adams St, Syracuse, NY 13210 Phone: 315-408-5854 | |
Shauna Thariath, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 725 East Adams St, 4th Fl, Syracuse, NY 13210 Phone: 315-464-5831 Fax: 315-464-2030 | |
Dr. Aisha Sultana Baig, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 750 East Adam St, Syracuse, NY 13210 Phone: 315-464-6323 Fax: 315-464-6322 | |
Megan A Pinnamaneni, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 750 E Adams St, Syracuse, NY 13210 Phone: 315-464-5420 | |
Steven David Blatt, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 725 East Adams St, 4th Fl, Syracuse, NY 13210 Phone: 315-464-5831 Fax: 315-464-2030 |